BRL 32872

Known as: BRL-32872 
 

Topic mentions per year

Topic mentions per year

1995-2007
012319952007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Atrial dilatation is commonly associated with atrial fibrillation (AF), but the electrophysiological mechanisms and the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Review
2002
Review
2002
BRL-32872 is a new antiarrhythmic drug with balanced class-III and class-IV actions as categorized by the Vaughan-Williams… (More)
Is this relevant?
2001
2001
Human ether-a-go-go-related gene (HERG) potassium channels are one primary target for the pharmacological treatment of cardiac… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1999
1999
Amongst the different pharmacological approaches to the treatment of cardiac arrhythmias, compounds with multiple… (More)
Is this relevant?
1998
1998
OBJECTIVE The effects of BRL-32872, azimilide and a selective blocker of the delayed rectifier potassium current, E-4031, were… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
1998
1998
The modulation of the protein kinase A-activated chloride current (PKA-I[Cl]) may lead to modification of the cardiac action… (More)
Is this relevant?
1998
1998
Class III antiarrhythmic agents have been shown to prevent reentrant arrhythmias but also to be responsible for initiating… (More)
Is this relevant?
1996
1996
In the search for novel antiarrhythmic agents, compounds with a diversity of electrophysiological actions have been suggested to… (More)
Is this relevant?
1995
1995
The effects of N-(3,4-dimethoxyphenyl)-N-[3[[2-(3,4-dimethoxyphenyl) ethyl] propyl]-4-nitrobenzamide hydrochloride (BRL-32872), a… (More)
Is this relevant?
1995
1995
The antifibrillatory potential of BRL-32872, a novel antiarrhythmic compound with K+ and Ca2+ channel blocking activities, was… (More)
Is this relevant?